Amneal Pharmaceuticals, Inc. (AMRX) Valuation — DCF & Advanced Analysis | MarketCI

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Navigation

Explore Analysis Investor Relations AI Assistant Compare Screener

Help Pricing Privacy Terms

Amneal Pharmaceuticals, Inc. (AMRX) Valuation — DCF & Advanced Analysis | MarketCI | MarketCI

AMRX

Market Closed

Amneal Pharmaceuticals, Inc.

NASDAQHealthcare Drug Manufacturers - Specialty & Generic

8.50K employees

CEO: Chirag K. Patel

Founded: 2018

$18.07

+$0.00(+NaN%)

Market Cap

5.77B

Beta

1.26

52W Range

N/A

Dividend Yield

0.00%

Overview Forecasts Fundamental Market Sentiment Valuation Ownership

Comprehensive Valuation

In-depth valuation analysis including DCF scenarios and peer comparisons.

AI Insight: Amneal's current price exceeds the PERT-weighted fair value by 9.4%, with wide valuation dispersion reflecting high uncertainty. Strong liquidity and growth contrast sharply with poor profitability and efficiency, heightening operational risk. Monte Carlo reveals substantial volatility and downside risk, indicating a speculative value range between $9.16 and $71.88.

Enhanced Football Field Analysis

Loading comprehensive valuation data...

Fetching multi-methodology valuation ranges...

Explore AMRX

Overview

Key metrics and AI-powered insights

Forecast

Price targets and earnings estimates

Fundamentals

Income, balance sheet and cash flow

Valuation

P/E, DCF and valuation multiples